1. Home
  2. AMRX vs WVE Comparison

AMRX vs WVE Comparison

Compare AMRX & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMRX
  • WVE
  • Stock Information
  • Founded
  • AMRX 2002
  • WVE 2012
  • Country
  • AMRX United States
  • WVE Singapore
  • Employees
  • AMRX N/A
  • WVE N/A
  • Industry
  • AMRX Biotechnology: Pharmaceutical Preparations
  • WVE Biotechnology: Pharmaceutical Preparations
  • Sector
  • AMRX Health Care
  • WVE Health Care
  • Exchange
  • AMRX Nasdaq
  • WVE Nasdaq
  • Market Cap
  • AMRX 2.7B
  • WVE 2.4B
  • IPO Year
  • AMRX N/A
  • WVE 2015
  • Fundamental
  • Price
  • AMRX $8.47
  • WVE $13.67
  • Analyst Decision
  • AMRX Strong Buy
  • WVE Strong Buy
  • Analyst Count
  • AMRX 5
  • WVE 10
  • Target Price
  • AMRX $10.00
  • WVE $21.30
  • AVG Volume (30 Days)
  • AMRX 1.1M
  • WVE 1.4M
  • Earning Date
  • AMRX 11-08-2024
  • WVE 11-12-2024
  • Dividend Yield
  • AMRX N/A
  • WVE N/A
  • EPS Growth
  • AMRX N/A
  • WVE N/A
  • EPS
  • AMRX N/A
  • WVE N/A
  • Revenue
  • AMRX $2,680,420,000.00
  • WVE $53,610,000.00
  • Revenue This Year
  • AMRX $17.56
  • WVE N/A
  • Revenue Next Year
  • AMRX $3.23
  • WVE N/A
  • P/E Ratio
  • AMRX N/A
  • WVE N/A
  • Revenue Growth
  • AMRX 12.32
  • WVE N/A
  • 52 Week Low
  • AMRX $4.16
  • WVE $3.50
  • 52 Week High
  • AMRX $9.48
  • WVE $16.74
  • Technical
  • Relative Strength Index (RSI)
  • AMRX 45.78
  • WVE 50.96
  • Support Level
  • AMRX $7.52
  • WVE $14.95
  • Resistance Level
  • AMRX $9.48
  • WVE $16.71
  • Average True Range (ATR)
  • AMRX 0.35
  • WVE 1.04
  • MACD
  • AMRX 0.02
  • WVE -0.28
  • Stochastic Oscillator
  • AMRX 48.59
  • WVE 14.72

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: